In Segment A, individuals will get distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. Added contributors will likely be enrolled within the identified monotherapy dosign regimen. In Phase B, participants will receive oral ruxolitinib and ABBV-744 is going to be specified as "include-on" therapy. In https://israelnbmyj.losblogos.com/31364751/the-2-minute-rule-for-abbv-744-and-other-brd4-inhibitors-comparison